Reactive oxygen species (ROS) are the by-product of normal metabolism
Recent trials have shown: Up to 20% body weight reduction with weekly GLP-1 agonists (Wilding et al., NEJM) Improvements in HbA1c, fasting glucose, and cardiovascular outcomes (Marso et al., NEJM) This drug class is now widely used for: Obesity (with or without diabetes) Type 2 diabetes PCOS-related insulin resistance Metabolic syndrome Common Side Effects and Patient Concerns Despite their benefits, GLP-1 agonists are not without risks or drawbacks
The TE literature and bariatric meta-analyses tell us it is the speed and magnitude that predict shedding risk, not a single cut-off
How it works Peptide Therapy: Stimulates specific pathways (e.g., growth-hormone signalling, tissue repair, metabolic activity)
The good news is that there is no report of B12 toxicity which means there is no limit to how much B12 can be taken by an otherwise healthy person
These treatments arent a onesizefitsall solution, but certain people tend to see the most significant benefits